Sigma Investment Counselors Inc. Increases Position in Johnson & Johnson $JNJ

Sigma Investment Counselors Inc. increased its position in Johnson & Johnson (NYSE:JNJ) by 2.6% in the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 10,236 shares of the company’s stock after purchasing an additional 264 shares during the period. Sigma Investment Counselors Inc.’s holdings in Johnson & Johnson were worth $1,564,000 at the end of the most recent reporting period.

Other hedge funds have also bought and sold shares of the company. GFG Capital LLC acquired a new position in Johnson & Johnson in the second quarter worth about $35,000. Stone House Investment Management LLC acquired a new position in Johnson & Johnson in the first quarter worth about $47,000. 1248 Management LLC acquired a new position in Johnson & Johnson in the first quarter worth about $48,000. von Borstel & Associates Inc. acquired a new position in Johnson & Johnson in the first quarter worth about $49,000. Finally, Harvest Fund Management Co. Ltd acquired a new position in Johnson & Johnson in the first quarter worth about $52,000. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the business’s stock in a transaction that occurred on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the completion of the transaction, the executive vice president directly owned 178,013 shares in the company, valued at approximately $31,652,491.53. The trade was a 24.08% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 0.16% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on JNJ shares. Daiwa Capital Markets upgraded Johnson & Johnson from a “neutral” rating to an “outperform” rating and set a $203.00 price target for the company in a research note on Monday. Erste Group Bank upgraded Johnson & Johnson from a “hold” rating to a “buy” rating in a research note on Wednesday, July 23rd. Morgan Stanley set a $190.00 target price on Johnson & Johnson in a research note on Wednesday, October 15th. Piper Sandler restated an “overweight” rating on shares of Johnson & Johnson in a research note on Thursday, July 17th. Finally, Argus set a $210.00 target price on Johnson & Johnson in a research note on Wednesday, October 15th. Two investment analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and eight have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $200.06.

Johnson & Johnson Stock Performance

Shares of NYSE JNJ opened at $193.78 on Tuesday. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50. The stock has a 50 day simple moving average of $180.89 and a 200-day simple moving average of $165.18. The company has a market cap of $466.68 billion, a PE ratio of 18.70, a P/E/G ratio of 2.27 and a beta of 0.40. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $194.48.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. The business had revenue of $24.02 billion during the quarter. Johnson & Johnson had a return on equity of 33.08% and a net margin of 27.26%. On average, equities research analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 9th. Stockholders of record on Tuesday, November 25th will be given a dividend of $1.30 per share. The ex-dividend date is Tuesday, November 25th. This represents a $5.20 annualized dividend and a dividend yield of 2.7%. Johnson & Johnson’s payout ratio is currently 50.19%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.